Mangoceuticals, Inc. (MGRX)
| Market Cap | 37.83M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17,701 |
| Shares Out | 15.32M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 232,888 |
| Open | 2.35 |
| Previous Close | 2.42 |
| Day's Range | 2.25 - 3.00 |
| 52-Week Range | 2.25 - 4.37 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MGRX
Mangoceuticals plans to connect consumers to licensed healthcare professionals through a recently launched website for the provision of care via telehealth on our customer portal and plan to also provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. To date, we have developed what we believe is a go-to-market strategy inclusive of product development, operations, marketing and advertising; however, we have not produced a sign... [Read more]
Financial Performance
Financial StatementsNews
Mangoceuticals, Inc. Announces Closing of $5 Million Initial Public Offering
DALLAS, TX / ACCESSWIRE / March 23, 2023 / Mangoceuticals, Inc. ("MangoRx" or the "Company") (NASDAQ:MGRX), a company focused on developing, marketing and selling a variety of men's health and wellnes...
Mangoceuticals, Inc. Announces Pricing of Initial Public Offering
IPO Shares to Commence Trading Today on Nasdaq under Ticker Symbol "MGRX" DALLAS, TX / ACCESSWIRE / March 21, 2023 / Mangoceuticals, Inc. ("MangoRx" or the "Company")(NASDAQ:MGRX), a company focused o...
Men's wellness products provider Mangoceuticals files and sets terms for a $5 million IPO
Mangoceuticals, which provides an erectile dysfunction product via telehealth, filed on Friday with the SEC to raise up to $5 million in an initial public offering.
Mangoceuticals IPO Registration Document (S-1)
Mangoceuticals has filed to go public with an IPO on the {Market}.